Visteon CEO sells shares, exercises stock options
Visteon Corp CEO and President Sachin Lawande reported a mix of stock option exercises and share sales in Visteon common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Visteon Corp CEO and President Sachin Lawande reported a mix of stock option exercises and share sales in Visteon common stock. On April 23–24, he exercised options to acquire 49,826 shares at a strike price of $66.98 per share and sold 49,826 shares in open-market transactions at prices generally around the low-to-mid $110s.
The filing notes these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 31, 2025, indicating they were scheduled in advance. Following the reported transactions, Lawande directly owns 231,339 shares of Visteon common stock.
Insights
Visteon’s CEO executed a pre-planned exercise-and-sell of options, with sizeable stock holdings remaining.
CEO and President Sachin Lawande exercised options for 49,826 Visteon shares at a strike price of $66.98 and sold an equal number of shares between roughly $110 and $115.27 per share. These are classic exercise-and-sell transactions that convert an existing option position into cash and common shares.
The filing states the trades were carried out under a Rule 10b5-1 trading plan adopted on July 31, 2025, suggesting they were scheduled rather than opportunistic. After the transactions, Lawande still directly holds 231,339 common shares, indicating he retains a substantial equity stake. Overall, this looks like routine liquidity and compensation management rather than a thesis-changing move.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 38,817 | $0.00 | $0.00 |
| Exercise | Common Stock | 38,817 | $66.98 | $2.60M |
| Sale | Common Stock | 1,300 | $110.81 | $144K |
| Sale | Common Stock | 4,850 | $112.64 | $546K |
| Sale | Common Stock | 19,822 | $113.52 | $2.25M |
| Sale | Common Stock | 12,045 | $114.40 | $1.38M |
| Sale | Common Stock | 800 | $115.27 | $92K |
| Exercise | Employee Stock Option (right to buy) | 11,009 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,009 | $66.98 | $737K |
| Sale | Common Stock | 11,009 | $110.09 | $1.21M |
Footnotes (8)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2025
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 - $110.27, inclusive. The reporting person undertakes to provide to Visteon Corporation, its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.57 - $110.83, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 - $112.99, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.03 - $114.02, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.03 - $115.02, inclusive.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.16 - $115.50, inclusive.
- F8. The option is exercisable to the extent of one third of the shares optioned after one year from the date of grant, two-thirds in two years and in full after three years.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Employee Stock Option (right to buy) financial
derivative security financial
open-market sale financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Visteon (VC) CEO Sachin Lawande report in this Form 4 filing?
Did Visteon (VC) CEO’s transactions involve stock option exercises?
What is the net effect of the Visteon (VC) CEO’s Form 4 activity?
AI-generated analysis. How Rhea-AI works. Not financial advice.